At a fixed SP of 80%, the panel of CA19-9 and CA-125 significantly improved SN in detecting PDAC (78% vs. 41%) as well as early stage PDAC (72% vs. 59%) from IPMN only, respectively, demonstrating that CA-125 was significantly complementary to CA19-9 in the detection of PDAC, as well as early stage PDAC from IPMN only. This evidence concerns the gene MUC16 and pancreatic intraductal papillary-mucinous neoplasm.